Bruce K. Patterson, MD is a leading researcher on the effects of viral pathogens on the human immune system. His pioneering technologies and findings have contributed to advances in detection, prognosis and treatment of patients infected with HIV, HPV and cervical cancer, COVID-19 and other disease.
Using PCR-driven in situ hybridization and flow cytometry to detect viral DNA and RNA within infected cells, Dr. Patterson and colleagues demonstrated that HIV entered and multiplied in the host cells in a stealthy fashion that eluded discovery. This groundbreaking work was published in the peer reviewed journal Science. He also developed a new method to investigate the effect of antiretroviral therapy within the infected host cell and published this discovery in the peer reviewed journal Lancet. Dr. Patterson continues his work on HIV-1pathogenesis and reservoirs at Stanford University School of Medicine, where he previously served as Medical Director of Diagnostic Virology at Stanford University Hospitals and Clinics, director of clinical virology, and co-director of the AIDS Research Center.
Dr. Patterson received his undergraduate degree in microbiology from the University of Michigan and his MD from Northwestern, where he later served as Chief Resident of Pathology at Northwestern Memorial Hospital. He has authored more than 150 manuscripts and book chapters.
Dr. Patterson serves as CEO of IncellDx, where he is developing a new paradigm for predicting, identifying and treating long COVID-19 and other viral pathogens that impair the immune system’s ability to function effectively.